Hinge Bio, Inc. is leveraging its proprietary Flex-Hinge antibody platform to develop the next-generation of bispecific and multispecific antibodies that bind with multi-handed cooperativity to both disease targets and effector cells. Hinge Bio’s streamlined chemical ligation process technology enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity, incorporating virtually any polypeptide, including gold standard targeting domains such as natural, unmodified Fabs, and effector molecules including growth factors, cytokines, receptor decoys and apoptosis agonists.